Related by context. All words. (Click for frequent words.) 79 multivariate Cox 79 multivariate logistic regression 78 multivariate analyzes 77 univariate analysis 77 multivariable logistic regression 77 logistic regression analysis 77 bivariate 76 covariate 76 logistic regression 76 Univariate 76 conditional logistic regression 76 logistic regression models 75 multiple logistic regression 75 nonparametric 74 logistic regression model 74 Logistic regression 74 Poisson regression 74 ANOVA 74 multivariable Cox 74 logistic regression analyzes 74 Kaplan Meier analysis 74 regression analyzes 73 multivariable analysis 73 proportional hazards 73 Multivariate analysis 73 Bonferroni correction 73 multiple linear regression 73 covariates 73 confidence intervals CIs 72 Multivariate logistic regression 72 univariate analyzes 72 Kaplan Meier method 72 chi squared 71 explanatory variables 71 binary logistic regression 71 intraobserver 71 multivariate analysis 71 variance ANOVA 71 Mantel Haenszel 70 interobserver 70 Multiple logistic regression 70 allele frequencies 70 generalized estimating 70 Univariate analysis 70 Kaplan Meier survival 70 Descriptive statistics 70 stepwise logistic regression 69 Linear regression 69 clinicopathological 69 HOMA IR 69 multivariate regression analysis 68 multivariate regression 68 Pearson correlation coefficient 68 interobserver reliability 68 Kruskal Wallis test 68 odds ratios ORs 68 Subgroup analyzes 68 preoperative PSA 68 bivariate analysis 68 MDRD 68 Subgroup analysis 68 rs# [004] 68 Wilcoxon rank sum 67 Multivariate 67 correlation coefficients 67 covariance 67 Pearson correlation coefficients 67 logistic regressions 67 Interrater reliability 67 immunohistochemical 67 histopathologic 67 F FDG PET 67 unpaired t 67 Bonferroni 66 meta analytic 66 MMSE score 66 meta regression 66 convergent validity 66 ROC curves 66 multivariable adjusted 66 covariance ANCOVA 66 interrater reliability 66 Kruskal Wallis 66 biochemical recurrence 66 prognostic variables 66 pairwise comparisons 66 Kaplan Meier 66 clinicopathological features 66 posttreatment 66 Logistic regression analysis 65 generalized linear 65 Pharmacokinetic parameters 65 Genotypic 65 Response Evaluation Criteria 65 Multivariable 65 multivariate 65 etiologic 65 symptomatic VTE 65 clinicopathologic 65 prognostic factors 65 NMIBC 65 Kaplan Meier curves 65 multivariate adjustment 65 Brief Psychiatric 65 linear regression analyzes 65 histopathological 65 K ras mutations 65 genotypic resistance 65 nomograms 65 immunohistochemical staining 65 carotid IMT 65 categorical variables 65 Multiple linear regression 65 affective psychosis 65 intraclass correlation coefficients 65 platelet reactivity 64 linear regression analysis 64 serum estradiol 64 prostate cancer CaP 64 colorectal adenoma 64 Histologic 64 Kaplan Meier curve 64 multivariable analyzes 64 nonfatal MI 64 rs# [001] 64 postintervention 64 definite stent thrombosis 64 Rating Scale BPRS 64 intact parathyroid hormone 64 estimated GFR 64 ultrasonographic 64 NIHSS 64 myocardial viability 64 Meta analyzes 64 histological subtype 64 comorbidity 64 histologic subtype 64 genotypic 64 epistasis 64 cytologic 64 SLN biopsy 64 regression analysis 64 ANCOVA 64 clinico pathological 64 intima media thickness 64 APOE genotype 64 hematopoietic cancers 64 immunohistochemical analysis 64 Multivariate analyzes 64 Quantitative RT PCR 64 prostate carcinoma 64 prognostic significance 64 rs# [002] 64 ADAS cog 64 EQ 5D 64 MetS 64 lymph node metastasis 63 prospectively defined 63 PSADT 63 recursive partitioning 63 HER2 expression 63 sensitivity specificity 63 subgroup analyzes 63 confounder 63 mammographic density 63 retest reliability 63 nomogram 63 retrospective cohort 63 Hazard Ratio HR 63 p = .# [002] 63 coronary stenosis 63 familial aggregation 63 Montgomery Åsberg Depression 63 PCa 63 χ 63 morphometric vertebral fractures 63 semiquantitative 63 ABCB1 63 glomerular filtration rate 63 thyroglobulin 63 KRAS mutation status 63 CVD mortality 63 BRCA2 mutation carriers 63 bivariate analyzes 63 residual confounding 63 CIN2 + 63 nodal metastases 63 lymphovascular invasion 63 IL#B 63 % CI #.#-#.# [006] 63 esophageal carcinoma 63 variant rs# 63 periprocedural 63 subclinical atherosclerosis 63 regression coefficient 63 transvaginal sonography 63 prespecified secondary 63 tHcy 63 endometrial thickness 63 Secondary efficacy endpoints 63 linear regressions 63 kidney allograft 62 PSA kinetics 62 LV ejection fraction 62 sociodemographic characteristics 62 Comorbidity 62 prognostic indicators 62 Index CDAI 62 LV dysfunction 62 regression coefficients 62 metabolite concentrations 62 Secondary endpoints 62 statistically nonsignificant 62 spirometric 62 adenoma recurrence 62 neoadjuvant chemotherapy 62 nonsignificant 62 dichotomous variables 62 distant metastasis 62 Haplotype 62 estrogen receptor ER 62 MDRD equation 62 premorbid 62 serum PSA 62 Pharmacodynamic 62 gene polymorphisms 62 RRM1 62 D dimer 62 obstructive coronary artery 62 ADAS Cog 62 histologic 62 node metastases 62 SNP rs# [002] 62 statistical significance p 62 % CI #.#-#.# [003] 62 #q# deletion syndrome 62 AST ALT 62 virological response 62 androgen suppression 62 HER2 overexpression 62 NHANES III 62 hematological parameters 62 #F FDG PET 62 immunostaining 62 pCR 62 posttest 62 hierarchical clustering 62 Regression analyzes 62 cTnI 62 Randomized trials 62 tumor histology 62 RECIST Response Evaluation Criteria 62 biochemical relapse 62 Multivariable logistic regression 62 locoregional 62 Kaplan Meier estimates 62 Primary endpoints 62 inferential statistics 62 histologic findings 62 NIHSS score 62 FDG-PET/CT 62 ADRB2 62 FDG PET imaging 62 qRT PCR 62 Symptom severity 62 tertiles 62 CC genotype 62 Solid Tumors RECIST 61 immunoblotting 61 subscale scores 61 5 HTTLPR 61 mRNA expression 61 Neuropsychiatric Inventory NPI 61 CR nPR 61 echocardiographic parameters 61 SLNB 61 locoregional recurrence 61 estimated glomerular filtration 61 TIMP 1 61 pT3 61 unmeasured confounders 61 monozygotic 61 linear regression 61 fasting insulin 61 Oncotype DX Recurrence Score 61 multivariable regression 61 P = .# 61 proband 61 homozygosity 61 NIH CPSI 61 differentially expressed genes 61 confidence interval #.#-#.# 61 subscores 61 sociodemographic variables 61 TRUS 61 biopsy Gleason 61 mg BID dose 61 intraclass correlation coefficient 61 pairwise 61 nonresponders 61 differential gene expression 61 ^ sup #m 61 Recurrence Score 61 β blockers 61 predictor variables 61 apolipoprotein B 61 genetic polymorphisms 61 elevated ALT 61 -#.# log# 61 neoadjuvant 61 prognostic factor 61 alexithymia 61 VKORC1 61 plasma cortisol 61 lumbar spine BMD 61 electrophysiologic 61 linkage disequilibrium 61 HOXB# 61 pT2 61 microsatellite instability 61 postoperative mortality 61 SUVmax 61 Ki# 61 PITX2 61 heterozygotes 61 specific antigen PSA 61 Crohn Disease Activity 61 QTc prolongation 61 predictive validity 61 anti JCV antibodies 61 transcranial Doppler ultrasound 61 Cronbach alpha 61 PSA nadir 61 neurodevelopmental outcome 61 lymphadenectomy 61 Depressive symptoms 61 Non inferiority 61 confounding variables 61 interrater 61 % Confidence Interval 61 randomized controlled trials RCTs 61 Thrombolysis 61 p = #.# [003] 61 Cystatin C 61 neurocognitive function 61 hip BMD 61 WOMAC pain 61 FEV ^ sub 61 Echocardiographic 61 advanced adenoma 61 noninferiority 61 confounders 61 periprocedural MI 61 logit 61 baseline HbA1c 61 urodynamic 61 antibody titer 61 metabolic parameters 61 prostate cancer PCa 61 interobserver agreement 61 Histopathologic 61 endometrial carcinoma 61 nonfatal myocardial infarction 61 pharmacokinetics PK 60 Main Outcome Measures 60 CORE OM 60 virologic failure 60 serum concentrations 60 laterality 60 XIENCE V PROMUS Stent 60 Observational studies 60 multivariable 60 FDG PET 60 adjuvant systemic 60 DAS# CRP 60 tertile 60 mRS 60 Alzheimer Disease Assessment 60 EUS FNA 60 nonmetastatic 60 pretest probability 60 quantile 60 ADCS ADL 60 F FDG uptake 60 Cardiorespiratory fitness 60 prospectively stratified 60 KRAS mutation 60 dyssynchrony 60 quantitative RT PCR 60 postoperative chemotherapy 60 APACHE II 60 ertapenem 60 hyperintense lesions 60 unfractionated heparin UFH 60 CYP#D# genotype 60 microvessel density 60 confidence interval CI 60 aspartate aminotransferase AST 60 NSABP B 60 rheumatoid factor 60 null hypothesis 60 HRCT 60 DLTs 60 contralateral breast cancer 60 progression TTP 60 sonographic findings 60 Sensitivity specificity 60 albumin creatinine ratio 60 baseline LDH 60 apolipoproteins 60 Reynolds Risk Score 60 correlational 60 Histological 60 tPSA 60 morphometric 60 ß = 60 lymphocytosis 60 inhibin B 60 prospective longitudinal 60 NNRTI resistance 60 relapsed MM 60 Cockcroft Gault 60 CHD mortality 60 Glomerular filtration rate 60 EURIDIS 60 IPAH 60 micrometastasis 60 cardiac troponin T 60 eNO 60 hyperinsulinemic euglycemic clamp 60 creatinine ratio 60 seropositivity 60 statistically significant p = 60 prospective multicentre 60 PCWP 60 breast cancer subtypes 60 HRQL 60 mucinous 60 pegylated interferon alfa 2b 60 HAQ DI 60 pharmacodynamic parameters 60 HBeAg negative patients 60 genomewide 60 hepatic lesions 60 apo B apo AI 60 albumin excretion rate 60 hormone receptor status 60 tumor necrosis 60 urothelial carcinoma 60 virologic responses 60 Wechsler Adult 60 lognormal 60 dose proportionality 60 Cytogenetic 60 KRAS mutations 60 liver histology 60 angiographically 60 bone scintigraphy 60 QIDS SR 60 pancreatic adenocarcinoma 60 potential confounders 60 plain radiographs 60 cystatin C 60 waist circumference WC 60 DAS# scores 60 doxorubicin docetaxel 60 genotype phenotype 60 radical prostatectomy RP 60 nonrandomized 60 QTc 60 prespecified 60 lymph node metastases 60 Main Outcome Measure 60 CHADS2 60 cTnT 60 BMI z 60 oncologic outcomes 60 Visual Analogue Scale VAS 60 TEAEs 60 MR spectroscopy 60 femoral neck BMD 60 PON1 activity 60 subtrochanteric 60 % CI #.#-#.# [007] 60 preintervention 60 serum HBV DNA 60 lymph node involvement 60 pharmacodynamic markers 59 nondiabetic patients 59 histologically confirmed 59 euthymic patients 59 Postoperative complications 59 secondary efficacy endpoint 59 RECIST criteria 59 TT genotype 59 GABRA2 59 COMT genotype 59 MADRS score 59 composite endpoint 59 urine cytology 59 clinically localized prostate 59 serum cortisol 59 Haptoglobin 59 nodal metastasis 59 ECG abnormalities 59 eGFR 59 enzyme immunoassay EIA 59 ABVD 59 psychosocial variables 59 = #.#-#.# 59 SNP rs# [001] 59 histopathologic findings 59 Immunohistochemical staining 59 dimensional echocardiography 59 LOCF 59 RT PCR assay 59 sociodemographic factors 59 haematologic 59 BRAF V#E mutation 59 Baseline characteristics 59 FDG uptake 59 serum cotinine 59 unmeasured confounding 59 gemcitabine carboplatin 59 Pharmacokinetic 59 bronchopulmonary dysplasia BPD 59 Score TOS 59 perioperative complications 59 STRIDE PD 59 eplerenone 59 virologic response 59 postoperative complication 59 ASCUS 59 Framingham Risk Score 59 CCyR 59 autonomic dysfunction 59 psychiatric comorbidity 59 Secondary endpoints included 59 mean ± SEM 59 plasma pharmacokinetics 59 hemodynamic variables 59 FDG PET scans 59 cognitive affective 59 VNTR 59 corrected QT interval 59 advanced neoplasia 59 methotrexate monotherapy 59 recurrent venous thromboembolism 59 echocardiographic 59 FOLFIRI 59 fraternal twin pairs 59 coronary calcification 59 genetic loci 59 achieved statistical significance 59 depressive symptom 59 cellularity 59 breast carcinoma 59 YMRS 59 comorbidities 59 Unified Parkinson Disease 59 HBeAg 59 regression equations 59 sleeve lobectomy 59 TNM staging 59 mL/min/#.# m 2 59 syndromal 59 androgen deprivation 59 subanalysis 59 HIV RNA 59 RE LY ® 59 glycosylated hemoglobin HbA1c 59 familial AF 59 d dimer 59 thromboembolic complications 59 DAS# [002] 59 fosamprenavir 59 radiotherapy RT 59 serum biomarkers 59 airway hyperresponsiveness 59 hsCRP 59 -#.# ± [002] 59 cerebral microbleeds 59 #.#ng/ml 59 thromboembolism 59 chronicity 59 baseline FEV 59 DCE MRI 59 adverse perinatal 59 contrast echocardiography 59 histologically 59 adnexal mass 59 Child Behavior Checklist 59 nonfasting triglyceride levels 59 tipranavir ritonavir 59 sociodemographic 59 multivariable adjustment 59 transcriptional profiling 59 Randomized controlled 59 cytoreductive nephrectomy 59 SCr 59 molecular subtypes 59 Doppler sonography 59 OGTT 59 perioperative mortality 59 coinfected patients 59 prognostically 59 T2DM 59 percutaneous vertebroplasty 59 transabdominal 59 DAS# remission 59 alkaline phosphatase ALP 59 advanced adenomas 59 somatoform disorders 59 urinary N telopeptide 59 = -#.# 59 transient elastography 59 Sensitivity analyzes 59 extrapyramidal symptoms 59 Secondary endpoints include 59 radiochemotherapy 59 retrospective cohort study 59 chest radiographs 59 multivariate adjusted 59 distant metastases 59 β = 59 highest tertile 59 sentinel lymph node biopsy 59 transthoracic echocardiography 59 System IPSS 59 μmol L 59 symptomatic intracerebral hemorrhage 59 κ 59 Regression analysis 59 laboratory abnormalities 59 colorectal neoplasia 59 vertebral fracture 59 ischemic lesions 59 homozygotes 59 subscore 59 CTEPH 59 viral kinetics 59 calculated creatinine clearance 58 oral glucose tolerance 58 chi ^ sup 58 isoprostane 58 empirically derived 58 Preoperative 58 plasma homocysteine 58 Histopathological 58 parasitaemia 58 anthropometric measures 58 familial clustering 58 epithelial tumors 58 doxorubicin cyclophosphamide 58 Lymph node 58 malignant lesions 58 galiximab 58 depressive symptomatology 58 allelic 58 Mendelian randomization 58 Randomized clinical trials 58 % CI #.#-#.# [005] 58 MTT assay 58 fasting plasma 58 carotid stenosis 58 ROC curve 58 histopathologic diagnosis 58 Lp PLA 2 58 postprocedure 58 creatinine clearance 58 pelvic lymphadenectomy 58 Scale PANSS 58 prospective observational studies 58 stratifying patients 58 perioperative morbidity 58 invasive carcinomas 58 UGT#A# * 58 lowest tertile 58 mg kg dose 58 axillary lymph node 58 longitudinal cohort study 58 extramedullary 58 polygenic 58 psychiatric morbidity 58 statistically significant correlations 58 Supplementary Appendix 58 rho = 58 Stent thrombosis 58 EBMT criteria 58 somatostatin analog 58 thyrotropin levels 58 postoperative pulmonary 58 Finite element 58 Zevalin consolidation 58 variogram 58 Scale cognitive subscale 58 NSTE ACS 58 metaanalysis 58 Severity MSCS score 58 Insulin sensitivity 58 Prostate specific antigen 58 leukocyte count 58 Western blotting 58 death reinfarction 58 Folfox 58 TURBT 58 rs# [003] 58 abacavir lamivudine 58 florbetaben 58 CYP #D# 58 carotid intima media 58 APTIVUS r 58 dosimetric 58 ER CHOP 58 sonographically guided 58 extracapsular extension 58 atypical hyperplasia 58 aminotransferase levels 58 subscales 58 EuroSCORE 58 reinfarction 58 pg ml 58 neuropathological 58 progesterone receptor PR 58 SerDes transceivers 58 preoperative chemotherapy 58 WAIS III 58 immunoreactivity 58 apparent diffusion coefficient 58 darunavir ritonavir 58 PANSS 58 probands 58 ECLS 58 cystatin 58 hematologic toxicity 58 abdominal adiposity 58 neurologic progression 58 gastric carcinoma 58 thiopurine 58 microarray experiments 58 KRAS status 58 timepoints 58 Suicidal ideation 58 SSc 58 recurrent VTE 58 methylenetetrahydrofolate reductase 58 hip resurfacing arthroplasty 58 HbA 1c 58 parous women 58 factorial 58 lactate dehydrogenase LDH 58 Angiographic 58 Y BOCS 58 Supplementary Table 58 #OHD 58 retrospectively analyzed 58 bivalirudin monotherapy 58 visceral adiposity 58 karyotypes 58 duplex ultrasonography 58 serum vitamin D 58 mycophenolate mofetil 58 adiponectin concentrations 58 LVEF 58 subthreshold 58 neuropsychological assessment 58 lipid abnormalities 58 CIMZIA ™ 58 stage IIIb IV 58 Correlation coefficients 58 CANCIDAS 58 hsCRP levels 58 Logistic regression analyzes 58 variography 58 histopathologic examination 58 fluorodeoxyglucose positron emission tomography 58 morphologic 58 GSTP1 58 albumin excretion 58 troponin T 58 BI RADS 58 liver metastasis 58 amisulpride 58 phylogenetic analyzes 58 bronchoalveolar lavage 58 T1a 58 neuroimaging studies 58 ESR1 58 prognostic indicator 58 Viral load 58 monozygotic twins 58 DRD2 58 residual platelet reactivity 58 Postoperative 58 Capacity FVC 58 RRs 58 T1c 58 susceptibility loci 58 fractional anisotropy 58 PCI ExTRACT TIMI 58 dichotomized 58 guaiac 58 serum leptin 58 ± SEM 58 exploratory endpoints 58 Phenotypic 58 SYNTAX 58 Tumor Response 58 r2 = 58 Estrogen Receptor 58 predictive biomarker 58 plasma lipid 58 annualized relapse 58 methodologic 58 variant allele 58 % CI #.#-#.# [004] 58 CIN3 58 Doxil ® 58 psychiatric comorbidities 58 gadolinium enhanced 58 HDRS 58 TIMI 58 chemosensitivity 58 Prognostic 58 secondary efficacy endpoints 58 atherogenic dyslipidemia 58 Prognostic significance 58 tipranavir r 58 serum prostate 57 p = #.# [002] 57 stepwise regression 57 recurrent DVT 57 neoadjuvant therapy 57 antiretroviral naïve 57 perinatal outcomes 57 scintigraphic 57 elevated LDH 57 Leydig cell 57 multicenter randomized controlled 57 longitudinal observational study 57 % CI #.#-#.# [001] 57 intima media thickness IMT 57 Negative Syndrome 57 arteriography 57 SELENA SLEDAI 57 chemoradiotherapy 57 liver biopsies 57 rCBF 57 paricalcitol 57 TOP2A 57 serum creatinine 57 â ‰ ¥ 57 prognostic biomarker 57 tirofiban 57 -#.# log# copies mL 57 Gram stain 57 FDA defined valvulopathy 57 CALGB 57 serum clusterin levels 57 atherosclerotic lesion 57 allele frequency 57 Immunohistochemical analysis 57 HORIZONS AMI trial 57 endophenotypes 57 urine albumin 57 clinically meaningful differences 57 indel 57 microalbumin 57 creatine kinase MB 57 helical CT 57 noncardiovascular 57 radiographic findings 57 Immunohistochemistry 57 thyroid peroxidase 57 affective disorders 57 surrogate endpoint 57 NYHA functional class 57 MMSE 57 μg liter 57 Likert 57 attain statistical significance 57 xenograft models 57 Pharmacokinetic PK 57 ACR# ACR# 57 metastatic lymph nodes 57 Prospective Randomized Trial 57 bleomycin 57 LVNC 57 Scale Cognitive Subscale 57 curative resection 57 SIMPADICO 57 serum creatinine levels 57 specified secondary endpoints 57 cTnT levels 57 Prognostic factors 57 symptomatology 57 FOLPI 57 lactate dehydrogenase 57 glycated hemoglobin HbA1c 57 hamartomas 57 unstable angina pectoris 57 plasma leptin 57 allelic variation 57 BEXXAR Therapeutic Regimen 57 psychometric properties 57 IgG antibody 57 TDR TDT 57 SF #v# 57 abnormal cytology 57 bronchial responsiveness 57 overnight polysomnography 57 noncarriers 57 alanine aminotransferase ALT 57 Cardiotoxicity 57 HRQoL 57 operable breast cancer 57 hematological relapse 57 left ventricular diastolic 57 multicentre randomized 57 taxane therapy 57 psychopathological symptoms 57 ALT elevation 57 desvenlafaxine succinate 57 hemoglobin Hb 57 adenotonsillectomy 57 EGFR mutation status 57 indels 57 lymphopenia 57 adjuvant therapies 57 SLC#A# [002] 57 State Examination MMSE 57 metachronous 57 Tasigna prolongs 57 grade interpolation 57 clomipramine 57 transcriptomic 57 serum IGF 57 microsatellite markers 57 Hb A1C 57 COL#A# 57 conventional coronary angiography 57 liver transplant recipients 57 transgene expression 57 hepatocellular carcinomas 57 PON1 57 median PFS 57 Immunohistochemical 57 pharmacokinetic parameters 57 Abnormal Involuntary Movement 57 postoperative AF 57 ABL1 57 ERCC1 57 HBeAg negative 57 neuropathologic 57 neutropaenia 57 neurodevelopmental impairment 57 % CI #.#-#.# [002] 57 APOC3 57 K#N 57 KRAS wild 57 PON1 gene 57 QTcF 57 male Wistar rats 57 demonstrated clinically meaningful 57 physiologic parameters 57 PREZISTA r arm 57 alanine aminotransferase 57 atheroma volume 57 HbA 1c levels 57 Inhibin B 57 empiric 57 AJCC 57 airway responsiveness 57 Clusterin 57 atherosclerotic vascular disease 57 CYP#C# [001] 57 p = NS 57 NCCTG N# 57 methacholine challenge 57 5alpha reductase 57 nonpharmacologic 57 perfusion abnormalities 57 diffusion tensor 57 serum testosterone 57 colorectal adenocarcinoma 57 subthreshold depression 57 urinary albumin 57 MSLT 57 radical cystectomy 57 telomere lengths 57 chemoradiation therapy 57 CT urography 57 seminal vesicle invasion 57 C#Y 57 anthropometric measurements 57 glomerular filtration 57 antigen PSA 57 #p# [003] 57 squamous